Drug interactions of new antiretroviral drugs

Serrano López de las Hazas, J.I.

doi:10.1016/S2173-5085(11)70007-7

Farmacia Hospitalaria

ISSN: 1130-6343

Farmacia Hospitalaria (Farm Hosp) is the official publication of the Spanish Society of Hospital Pharmacists (SEFH), a professional and scientific organization that currently has about 4.351 members.

The Mission of Farm Hosp is to be the support for health professionals for expanding the influence of projects, publications, and training programs, and to promote the exchange of experiences.

Vision Farm Hosp is:
- to increase the state of knowledge about the hospital pharmacy and whose actions should increase the adequate and safe use of medicines and health products.
- to be an instrument of exchange and dissemination of scientific knowledge of pharmacy practice through the best use and safe medication and health outcomes.

It is a peer-reviewed double-blind scientific journal aimed at publishing in the broad field of Hospital Pharmacy advances in Pharmacy Services. This journal included the following topics: Drug evaluation. Quality of life. Patient Reported Outcome Measures (PROMs), and Patient Reported Experience Measures (PREMs) in the use of drugs. Monitoring medication. Pharmaceutical compounding. Medication administration. Management of Pharmacy Services (logistics, quality control). Technologies and information systems in the process of using medication. Medical devices. Patient Education. Pharmacist´s role in the society and /or in the Health System in Spain, and other topics related to clinical, scientific, and institutional role of hospital pharmacists.

Farmacia Hospitalaria publishes bimonthly (6 issues yearly) originals, short originals, reviews, clinical cases, special articles, protocols, consensus documents, clinical guidelines, letters to the editor, editorials.

All the articles are published in Spanish and English language regardless of the language in which they are received.

Farmacia Hospitalaria is an Open Access journal, whose content is available free of charge to users or their institutions. Users are authorised to read, download, copy, distribute, print, search, or link to entire texts of the articles in this journal without prior permission from the editor or author, according to the BOAI definition of Open Access. The papers may be re-used under the terms of the Creative Commons 4.0 license. (CC BY-NC-ND). Such use shall be subject to authorisation from SEFH, the journal owner.

Farmacia Hospitalaria journal charges no fees for submission of papers or publication of articles.

Adherence to international ethics recommendations

Manuscripts must follow the most recent recommendations of the International Committee of Medical Journal Editors (available at http://www.icmje.org).

The articles published in Farmacia Hospitalaria are indexed in PubMed and other 17 date bases:
- Evaluation databases: MEDLINE, DOAJ, Scopus, Latindex y Scimago Journal and Country Rank (SJR). Índice H: 18, quartile 3 (Medicine, miscellaneous / Pharmacology)
- Bibliographic databases: CINHAL, EMBASE Excerpta Medica, Índice Bibliográfico Español en Ciencias de la Salud (IBECS), Índice Español de Ciencia Y Tecnología (ICyT), Índice Médico Español (IME), International Pharmaceutical Abstracts (IPA).
- Journal collections: Dialnet, Medes, Scientific Electronic Library Online (SciELO), REDIB, ScienceDirect, ClinicalKey.

Farmacia Hospitalaria ha recibido Factor de Impacto (JCR) por primera vez en 2023.
Guía para autores - Envío de manuscritos

Farmacia Hospitalaria has received its first journal Impact Factor (JCR) in 2023.
Instructions for authors - Submit an article

Indexed in:

Web of Science, Scopus, Scimago Journal and Country Rank (SJR), Índice H: 18, CINHAL, EMBASE Excerpta Medica, Índice Bibliográfico Español en Ciencias de la Salud (IBECS), Índice Español de Ciencia Y Tecnología (ICyT), Índice Médico Español (IME), International Pharmaceutical Abstracts (IPA), MEDLINE, DOAJ, Dialnet, Latindex, Medes, Scientific Electronic Library Online (SciELO), REDIB.

A systematic review was made of the drug interactions of new antiretroviral drugs. In order to do this a search was made in Pubmed to find articles published from January 2007 to September 2009 and the full-text articles which contained information about new antiretroviral drugs were selected. This search was then complemented with information from the technical specifications of the drugs and consultations made on webpages specialized in antiretroviral interactions: www.interaccioneshiv.com and www.hiv-druginteractions.org. The information about the possible interactions of new antiretroviral drugs with one another and with the therapeutic groups which are most widely used in patients infected with the human immunodeficiency virus was analyzed.

Keywords:

Systematic review

Antiretroviral therapy

Drug interactions

Darunavir

Etravirine

Maraviroc

Raltegravir

Resumen

Se realiza una revisión sistemática sobre interacciones medicamentosas de los nuevos fármacos antirretrovirales. Para ello se realiza una búsqueda en Pubmed de artículos publicados entre enero de 2007 y septiembre de 2009 y se consideraron los artículos disponibles a texto completo que aportaban alguna información sobre los nuevos antirretrovirales. Esta búsqueda fue complementada a su vez con la información de las fichas técnicas de los productos y consultas en las páginas web específicas de interacciones de antirretrovirales: www.interaccioneshiv. com y www.hiv-druginteractions.org. Se analiza la información de las posibles interacciones de los nuevos antirretrovirales entre sí, y con los grupos terapéuticos más frecuentemente utilizados en pacientes con el virus de la inmunodeficiencia humana.

Palabras clave:

Revisión sistemática

Terapia antirretroviral

Interacciones medicamentosas

Darunavir

Etravirina

Maraviroc

Raltegravir

Full text is only aviable in PDF

References

[1.]

K. Seden, D. Back, S. Khoo.

Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.

J Antimicrob Chemother, 64 (2009), pp. 5-8

http://dx.doi.org/10.1093/jac/dkp152 | Medline

[2.]

M.M. De Maat, A. De Boer, C.H. Koks, J.W. Mulder, P.L. Meenhorst, E.C. Van Gorp, et al.

Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care.

J Clin Pharm Ther, 29 (2004), pp. 121-130

[3.]

S. Shah, J. McGowan, B. Opulski, A. Lieblein, A. Saperstein.

Identification of Drug Interactions Involving ART in New York City HIV Specialty Clinics.

CROI; Poster, (2007),

[4.]

S.H. Khoo.

O121 Drug interactions that really matter. University of Liverpool, Liverpool, UK from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK 9–13 November 2008.

Journal of the International AIDS Society, 11 (2008), pp. O6

[5.]

D.A. Rastegar, A.M. Knight, J.S. Monolakis.

Antiretroviral medication errors among hospitalized patients with HIV infection.

Clin Infect Dis, 43 (2006), pp. 933-938

http://dx.doi.org/10.1086/507538 | Medline

[6.]

A. Walubo.

The role of cytochrome P450 in antiretroviral drug interactions.

Expert Opin Drug Metab Toxicol, 3 (2007), pp. 583-598

http://dx.doi.org/10.1517/17425225.3.4.583 | Medline

[7.]

K.C. Brown, S. Paul, A.D. Kashuba.

Drug interactions with new and investigational antiretrovirals.

Clin Pharmacokinet, 48 (2009), pp. 211-241

Medline

[8.]

A. Judith, M.D. Aberg.

Drug-Drug Interactions With newer antiretroviral agents.

Top HIV Med, 16 (2008), pp. 146-150

Medline

[9.]

J.J. Kiser.

Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.

Curr Opin HIV AIDS, 3 (2008), pp. 330-341

http://dx.doi.org/10.1097/COH.0b013e3282fbaa6b | Medline

[10.]

M.C. Long, J.R. King, E.P. Acosta.

Pharmacologic aspects of new antiretroviral drugs.

Curr HIV/AIDS Rep, 6 (2009), pp. 43-50

Medline

[11.]

L. Dickinson, S. Khoo, D. Back.

Pharmacokinetics and drug-drug interactions of antiretrovirals: An update.

Antiviral Research, 85 (2010), pp. 176-189

http://dx.doi.org/10.1016/j.antiviral.2009.07.017 | Medline

[12.]

S.M. Robertson, S.R. Penzak, A. Pau.

Drug interactions in the management of HIV infection: an update.

Expert Opin Pharmacother, 8 (2007), pp. 2947-2963

http://dx.doi.org/10.1517/14656566.8.17.2947 | Medline

[13.]

J. Moltó, M. Valle, B. Clotet.

Pharmacological interactions with darunavir.

Enferm Infecc Microbiol Clin, 26 (2008), pp. 43-50

Medline

[14.]

D. Back, V. Sekar, R.M. Hoetelmans.

Darunavir: pharmacokinetics and drug interactions.

Antivir Ther, 13 (2008), pp. 1-13

Medline

[15.]

Ficha técnica de Prezista® (darunavir) [Internet document]. EMEA European Medicines Agency [accessed 2009 Jun 1]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/prezista/emea-combined-h707es.pdf.

[16.]

Interaccioneshiv.com [internet datebase]. Hospital Clínic – IDIBAPS Barcelona [accessed 2009 June 1]. Available from: http://www.interaccioneshiv.com/Buscar.asp.

[16.]

http://www. hiv-druginteractions.org/ [internet datebase]. University of Liverpool, http://www.hiv-druginteractions.org/ [internet datebase]. University of Liverpool [accessed 2009 Jun 1]. Available from: http://www.hiv-druginteractions.org/frames.asp?drug/drg_main.asp.

[18.]

J. Madruga, P. Cahn, R. Haubrich, et al.

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomised, doubleblind, placebo-controlled trial.

Lancet, 370 (2007), pp. 29-38

http://dx.doi.org/10.1016/S0140-6736(07)61047-2 | Medline

[19.]

A. Lazzarin, T. Campbell, B. Clotet, et al.

Efficacy an safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patient in DUET-2: 24-week results from a randomised, doubleblind, placebo-controlled trial.

Lancet, 370 (2007), pp. 39-48

http://dx.doi.org/10.1016/S0140-6736(07)61048-4 | Medline

[20.]

Ficha técnica de Intelence® (etravirina) [Internet document] EMEA European Medicines Agency [accessed 2009 Jun 1]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/intelence/emea-combined-h900es.pdf.

[21.]

V. Soriano, E. Poveda.

Pharmacokinetics, interactions and mechanism of action of maraviroc.

Enferm Infecc Microbiol Clin, 26 (2008), pp. 12-16

Medline

[22.]

J.M. Emmelkamp, J.K. Rockstroh.

CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions−review of the literature.

Eur J Med Res, 12 (2007), pp. 409-417

Article

[23.]

Ficha técnica de Celsentri® (maraviroc) [Internet document]. EMEA European Medicines Agency [accessed 2009 Jun 1]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/celsentri/emea-combined-h811es.pdf.

[24.]

Ficha técnica de Isentress® (raltegravir) [Internet document]. EMEA European Medicines Agency [accessed 2009 Jun 1]. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/isentress/emea-combined-h860es.pdf.

[25.]

R.W. Falcon, T.N. Kakuda.

Drug interactions between HIV protease inhibitors and acid-reducing agents.

Clin Pharmacokinet, 47 (2008), pp. 75-89

http://dx.doi.org/10.2165/00003088-200847020-00001 | Medline

[26.]

S.M. McCabe, P.F. Smith, Q. Ma, G.D. Morse.

Drug interactions between proton pump inhibitors and antiretroviral drugs.

Expert Opin Drug Metab Toxicol, 3 (2007), pp. 197-207

http://dx.doi.org/10.1517/17425255.3.2.197 | Medline

[27.]

E. Pontali.

Interactions of antiretroviral drugs with anti-infectives and other antiretrovirals.

Chemotherapy, 53 (2007), pp. 26-29

http://dx.doi.org/10.1159/000098247 | Medline

[27.]

G.M. Ray.

Antiretroviral and statin drug-drug interactions.

Cardiol Rev, 17 (2009), pp. 44-47

http://dx.doi.org/10.1097/CRD.0b013e3181903b7f | Medline

[29.]

E.M. Yakiwchuk, M.M. Foisy, C.A. Hughes.

Complexity of interactions between voriconazole and antiretroviral agents.

Ann Pharmacother, 42 (2008), pp. 698-703

http://dx.doi.org/10.1345/aph.1K530 | Medline

☆

Part of the content of this article was presented to the “Jornadas de Actualización en el tratamiento de la infección por el VIH” (Conference on Updating HIV treatment), organised by the Government of Catalonia Health Department on 10 June in Barcelona.

Tools

Publish in

Farmacia Hospitalaria

Farmacia Hospitalaria follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

Indexed in:

Follow us:

Subscribe to our newsletter